Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 6

Role of tipranavir in treatment of patients with multidrug-resistant HIV

Authors Joshua D Courter, Colleen J Teevan, Michael H Li, et al

Published Date September 2010 Volume 2010:6 Pages 431—441

DOI http://dx.doi.org/10.2147/TCRM.S4207

Published 23 September 2010

Joshua D Courter1,2, Colleen J Teevan1, Michael H Li1, Jennifer E Girotto1,2, Juan C Salazar1,2,3
1University of Connecticut School of Pharmacy, Storrs, 2Connecticut Children’s Medical Center, Hartford, 3University of Connecticut School of Medicine, Hartford, Connecticut, USA

Abstract: The worldwide emergence of multidrug-resistant human immunodeficiency virus (HIV)-1 strains has the driven the development of new antiretroviral (ARV) agents. Over the past 5 years, HIV-entry and integrase inhibitor ARVs, as well as improved non-nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), have become available for treatment. It is important to assess how these new ARVs might be most judiciously used, paying close attention to viral susceptibility patterns, pharmacodynamic parameters, and the likelihood that patients will adhere to their therapy. Herein we review published material in Medline, EMBASE, and ISI for each antiretroviral agent/classes currently approved and summarize the available data on their efficacy, safety, and pharmacologic parameters. We focus on the role of tipranavir, a recently approved nonpeptidic PI, for treating HIV-infected children, adolescents, and adults with a history of multidrug-resistant HIV.

Keywords: tipranavir, HIV, multidrug resistance

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Preferences for oral versus intravenous adjuvant chemotherapy among early breast cancer patients

Ishitobi M, Shibuya K, Komoike Y, Koyama H, Inaji H

Patient Preference and Adherence 2013, 7:1201-1206

Published Date: 22 November 2013

Relationship between lenticular power and refractive error in children with hyperopia

Tomomatsu T, Kono S, Arimura S, Tomomantsu Y, Matsumura T, Takihara Y, Inatani M, Takamura Y

Clinical Ophthalmology 2013, 7:601-606

Published Date: 24 March 2013

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi

Sapi E, Kaur N, Anyanwu S, Luecke DF, Datar A, Patel S, Rossi M, Stricker RB

Infection and Drug Resistance 2011, 4:97-113

Published Date: 3 May 2011

Long-term histological comparison between near-infrared irradiated skin and scar tissues

Yohei Tanaka, Kiyoshi Matsuo, Shunsuke Yuzuriha

Clinical, Cosmetic and Investigational Dermatology 2010, 3:143-149

Published Date: 25 November 2010

Emerging clinical role of ranolazine in the management of angina

David S Vadnais, Nanette K Wenger

Therapeutics and Clinical Risk Management 2010, 6:517-530

Published Date: 14 October 2010

Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide

Katri Elina Clemens, Eberhard Klaschik

Therapeutics and Clinical Risk Management 2010, 6:77-82

Published Date: 11 February 2010